Wave Life Sciences LTD DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Wave Life Sciences Ltd. is seeking shareholder approval to restructure its corporate group by redomiciling its parent company to Delaware, USA.
NASDAQ
DEF: Wave Life Sciences Prepares for 2025 AGM Amidst Continued Losses and Strategic Pipeline Advancements
Wave Life Sciences Ltd. has released its definitive proxy statement for the 2025 Annual General Meeting, detailing proposals for director elections, auditor re-appointment, executive and non-employee director compensation, and a significant increase in shares available for its equity incentive plan, while reporting continued net losses despite pipeline progress and recent capital raises.
NASDAQ
Wave Life Sciences has scheduled its 2024 Annual General Meeting (AGM) for August 6, 2024, outlining proposals including the election of directors, auditor re-appointment, executive compensation approval, and an amendment to the equity incentive plan.